Article

Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia

Cancer (impact factor: 4.77). 02/2009; 115(5):1100 - 1108. DOI:10.1002/cncr.24107 pp.1100 - 1108

ABSTRACT BACKGROUND:The objectives were to compare infections during different intensities of therapy in children with acute myeloid leukemia (AML).METHODS:Subjects were children enrolled in Children's Cancer Group 2891 with AML. In phase 1 (induction), patients were randomized to intensive or standard timing. In phase 2 (consolidation), those with a family donor were allocated allogeneic stem cell transplantation (SCT); the remainder were randomized to autologous SCT or chemotherapy. This report compares infections between different treatments on an intent-to-treat basis.RESULTS:During phase 1, intensive timing was associated with more bacterial (57.7% vs 39.4%; P < .001), fungal (27.4% vs 9.9%; P < .001), and viral (14.0% vs 3.9%; P < .001) infections compared with standard timing. During phase 2, chemotherapy was associated with more bacterial (56.5% vs 40.1%; P = .005), but similar fungal (9.5% vs 6.1%; P = 1.000) and viral (4.2% vs 12.9%; P = .728) infections compared with allogeneic SCT. No differences between chemotherapy and autologous SCT infections were seen. Fatal infections were more common during intensive compared with standard timing induction (5.5% vs 0.9%; P = .004). Infectious deaths were similar between chemotherapy, autologous SCT, and allogeneic SCT.CONCLUSIONS:Prevalence of infection varies depending on the intensity and type of treatment. This information sheds insight into the mechanisms behind susceptibility and outcome of infections in pediatric AML. Cancer 2009. © 2009 American Cancer Society.

0 0
 · 
0 Bookmarks
 · 
19 Views

Keywords

acute myeloid leukemia
 
allogeneic SCT
 
autologous SCT
 
autologous SCT infections
 
cell transplantation
 
Children's Cancer Group 2891
 
different intensities
 
different treatments
 
family donor
 
Fatal infections
 
infection varies
 
infections
 
information sheds insight
 
pediatric AML
 
phase 1
 
phase 2
 
similar fungal
 
standard timing
 
standard timing induction
 
© 2009 American Cancer Society